lenvatinib increases progression free survival with everolimus in metastatic renal cell carcinoma
Published 9 years ago • 405 plays • Length 4:05Download video MP4
Download video MP3
Similar videos
-
1:32
phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinoma
-
1:19
phase 2 trial of lenvatinib and everolimus for metastatic renal cell carcinoma
-
1:32
three-arm trial of lenvatinib and everolimus for metastatic renal cell carcinoma
-
2:06
lenvatinib plus pembro for arcc - update on the clear study
-
3:42
lenvatinib and everolimus in relapsed/refractory mrcc
-
5:32
lenvatinib and everolimus for advanced rcc
-
10:55
ikcs 2020: phase 2 trial of lenvatinib at 2 starting doses everolimus in renal cell carcinoma (rcc)
-
0:45
dr. choueiri on fda approval of lenvatinib/everolimus in rcc
-
2:13
dr. hutson on lenvatinib/everolimus combo in rcc
-
4:28
metastatic renal cell carcinoma: lenvatinib phase ii data
-
2:37
lenvatinib/everolimus in refractory mrcc
-
3:39
managing patients on lenvatinib/everolimus in mrcc
-
1:14
dr. larkin on lenvatinib plus everolimus in patients with rcc
-
5:14
lenvatinib plus pembrolizumab after progression on immune checkpoint inhibitors for metastatic rcc
-
10:06
lenvatinib and pembrolizumab compared to sunitinib for advanced renal cell carcinoma
-
7:03
lenvatinib breakthrough designation, new drug applications for nsclc and sts, and more
-
2:51
practical experience with lenvatinib/everolimus in rcc
-
6:42
the role of lenvatinib in advanced rcc
-
5:42
meteor trial: cabozantinib vs everolimus in advanced renal cell carcinoma